Search Results - "Cudkowicz, M."

Trial of Antisense Oligonucleotide Tofersen for ALS.

Authors: Miller, T. M. Cudkowicz, M. E. Genge, A. et al.

Source: New England Journal of Medicine. 9/22/2022, Vol. 387 Issue 12, p1099-1110. 12p.

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS.

Authors: Miller, T. Cudkowicz, M. Shaw, P. J. et al.

Source: New England Journal of Medicine. 7/9/2020, Vol. 383 Issue 2, p109-119. 11p.

Revised statistical motor unit number estimation in the Celecoxib/ALS trial.

Authors: Shefner, J. M. Cudkowicz, M. E. Zhang, H. et al.

Source: Muscle & Nerve. Feb2007, Vol. 35 Issue 2, p228-234. 7p.

ALS and unproven treatments: what should patients and physicians do?

Authors: Shefner JM Cudkowicz M

Source: Neurology Today. 2008 Sep 18, Vol. 8 Issue 18, p5-7. 3p.

Theme 09 - Clinical Trials and Trial Design.

Authors: Badri, S. Mason, J. Paganoni, S. et al.

Source: Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. Nov2022 Suppl 1, Vol. 23 Issue 1, p133-149. 17p.

The ALS Patient Care Database: Insights into End-of-Life Care in ALS.

Authors: Mandler, RN Anderson Jr, FA Miller, RG et al.

Source: Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders. Dec2001, Vol. 2 Issue 4, p203-208. 6p. 2 Charts, 4 Graphs.

106 - Mesenchymal Stem/Stromal Cells: CONSIDERATION OF COMPARTMENT EFFECT ON BIOMARKER ANALYSIS: LESSONS LEARNED FROM BRAINSTORM'S PHASE III CLINICAL TRIAL EVALUATING MSC-NTF CELL THERAPY IN ALS.

Authors: Blondheim-Shraga, N. Kaspi, H. Levy, Y.S. et al.

Source: Cytotherapy (Elsevier Inc.). 2023 Supplement, Vol. 25 Issue 6, pS39-S39. 1p.

Minocycline for patients with ALS

Authors: Leigh, Peter N Meininger, V Bensimon, G et al.

Source: Lancet Neurology. Feb2008, Vol. 7 Issue 2, p119-120. 2p.

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

Authors: Cudkowicz M Drory VE Chio A et al.

Source: JAMA neurology [JAMA Neurol] 2026 May 01; Vol. 83 (5), pp. 471-480.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE

An Expanded Access Protocol of RNS60 in Amyotrophic Lateral Sclerosis.

Authors: Addy G Scirocco E Gelevski D et al.

Source: Muscle & nerve [Muscle Nerve] 2025 Jul; Vol. 72 (1), pp. 124-129. Date of Electronic Publication: 2025 Mar 21.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Authors: Michaelis T Lindestam Arlehamn CS Johansson E et al.

Source: Nature [Nature] 2026 Apr; Vol. 652 (8108), pp. E2.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE; In Process

ALS untangled #83: clenbuterol.

Authors: Burgess A Allen O Barkhaus P et al.

Source: Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2026 Mar 08, pp. 1-8. Date of Electronic Publication: 2026 Mar 08.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101587185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2167-9223 (Electronic) Linking ISSN: 21678421 NLM ISO Abbreviation: Amyotroph Lateral Scler Frontotemporal Degener Subsets: MEDLINE

Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Authors: Michaelis T Lindestam Arlehamn CS Johansson E et al.

Source: Nature [Nature] 2025 Nov; Vol. 647 (8091), pp. 970-978. Date of Electronic Publication: 2025 Oct 01.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.

Authors: Videnovic A Coffey CS Klerman EB et al.

Corporate Authors: Videnovic A Coffey CS Klerman EB et al.

Source: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2025 Nov; Vol. 40 (11), pp. 2445-2456. Date of Electronic Publication: 2025 Sep 06.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov Disord Subsets: MEDLINE

Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome.

Authors: Protic D Breeze E Mendoza G et al.

Source: SAGE open medicine [SAGE Open Med] 2024 Sep 29; Vol. 12, pp. 20503121241282401. Date of Electronic Publication: 2024 Sep 29 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 101624744 Publication Model: eCollection Cited Medium: Print ISSN: 2050-3121 (Print) Linking ISSN: 20503121 NLM ISO Abbreviation: SAGE Open Med Subsets: PubMed not MEDLINE

Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis.

Authors: Sîrbulescu RF Nicholson K Kawai K et al.

Source: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2024 Jul 15; Vol. 38 (13), pp. e23796.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE

Artificial intelligence in neurology: opportunities, challenges, and policy implications.

Authors: Voigtlaender S Pawelczyk J Geiger M et al.

Source: Journal of neurology [J Neurol] 2024 May; Vol. 271 (5), pp. 2258-2273. Date of Electronic Publication: 2024 Feb 17.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE

Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial.

Authors: Smith AG Singleton JR Aperghis A et al.

Corporate Authors: Smith AG Singleton JR Aperghis A et al.

Source: JAMA neurology [JAMA Neurol] 2023 Dec 01; Vol. 80 (12), pp. 1334-1343.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Equivalence Trial

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE

A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial.

Authors: Wong KH Day GS Torner JC et al.

Source: Neurology open access [Neurol Open Access] 2025 Jun; Vol. 1 (2). Date of Electronic Publication: 2025 Apr 23.

Publication Type: Journal Article

Journal Info: Publisher: Wolters Kluwer Health Inc. on behalf of the American Academy of Neurology Country of Publication: United States NLM ID: 9919033199906676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2998-7601 (Electronic) Linking ISSN: 29987601 NLM ISO Abbreviation: Neurol Open Access Subsets: PubMed not MEDLINE

Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.

Authors: Quintana M Saville BR Vestrucci M et al.

Corporate Authors: Quintana M Saville BR Vestrucci M et al.

Source: Annals of neurology [Ann Neurol] 2023 Sep; Vol. 94 (3), pp. 547-560. Date of Electronic Publication: 2023 Jun 22.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE